NC-DOLE-FOOD-NC
16.4.2020 21:32:09 CEST | Business Wire | Press release
Dole Food Company announced today that in an effort to help with the COVID-19 crisis, Dole and its associated growers have so far donated more than two million pounds of fresh produce to recipients along its supply chain, from local food banks in the U.S. to the communities in Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005885/en/
“The virus is ruthless, and we have seen the brutal impact it has had on people—directly to their health and their income,” stated Johan Linden, CEO of Dole Food Company. “We want to answer the needs of the communities around our operations and do what we can to strengthen them during this moment of hardship.”
Dole recognizes these donations alone will not solve the food needs issue brought on by the coronavirus, but believes that we should all do what we can to help those around us. Dole is committed to continuing these efforts during this crisis.
Vince Hall, CEO of Feeding San Diego, an organization whose mission is to connect every person facing hunger with nutritious meals, shared his comments on Dole’s actions.
“While medical providers and first responders battle the COVID-19 crisis, Feeding San Diego is battling unprecedented hunger across San Diego County. One of our most important allies in this fight is Dole Food Company, a significant employer at the Port of San Diego. Dole continues to regularly donate large amounts of nutritious fresh fruit, especially bananas, which are very popular in the community and contribute to good health. Dole is to be commended for helping Feeding San Diego take care of those in need all year round, but especially during the current health crisis.”
In addition to San Diego, Dole has made donations in other U.S. cities including New York, Philadelphia, Charlotte, Houston, Los Angeles.
In Latin America, where Dole grows its tropical fruits, such as bananas and pineapple, the crisis is also hitting hard, and the company is supporting those rural communities where food security is most at risk. In the Aguan Valley of Honduras, for example, in addition to fruit Dole is distributing household staples such as rice, beans and cooking oil to employees and local communities. Beyond food, the company is also providing masks, sanitizing gel, testing kits and other health supporting supplies. Similar support is happening for communities in Costa Rica, Ecuador, Guatemala and Colombia including the provision of over 15,000 personal hygiene kits to aid in the prevention of infection.
“As an important local employer, it is our duty to support local communities. The consequences of this crisis are just starting to be felt here and the need for social support will continue to be felt in the weeks and months to come,” stated Renato Acuña, President of Dole Fresh Fruit Latin America. “Our local foundations and those of our associated producers are actively working on the ground and on the front line of this crisis, and Dole will provide additional support as long as necessary.”
The Dale Foundation, funded by Dole and its Ecuadorian growers, is using its medical staff and facilities to get the word out to the community on the importance of COVID-19 prevention, identifying high risk citizens to help them undertake the proper care, advancing purchases of medication that can help with respiratory illness, and continuing to operate its health clinics and provide remote medical services for its patients in the agricultural community.
Dole is also supporting those working on the front lines of the crisis by donating to hospitals in various countries where it operates and working with civil authorities to provide local aid.
For example, in the U.S., Dole has joined national produce distributor PRO*ACT, and other produce partners, to bring fresh produce to the tables of healthcare workers and their families during the COVID-19 crisis. The ‘Feeding our Frontlines’ program (www.producepartners.org ) provides boxes of fresh produce for healthcare employees to take home at the end of a long shift as a way of saying “thank you” to those taking care of us."
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005885/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
